Skip to main content
. 2021 May 20;7:57. doi: 10.1038/s41523-021-00244-6

Fig. 5. Progression-free survival by baseline disease characteristics.

Fig. 5

Progression-free survival was determined in the intention-to-treat population, based on Independent Review Committee assessments. A forest plot for progression-free survival for GV compared with capecitabine is shown by baseline disease characteristics. The black square represents the hazard ratio while the odds ratios (95% CIs) are denoted by black lines.